How Did Pfizer Perform in 3Q17?
Pfizer’s revenue trends
In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis. In 3Q17 and the first nine months of 2017, Pfizer reported net income of $2.8 billion and $9.0 billion, respectively, compared to $1.4 billion and $6.4 billion in the corresponding periods of 2016.
In 3Q17, Pfizer reported diluted earnings per share (or EPS) of $0.47 compared to $0.22 in 3Q16. Pfizer reported YTD September 2017 diluted EPS of $1.49 compared to $1.04 in YTD September 2016. In 3Q17, Pfizer reported adjusted income and adjusted diluted EPS of $4.1 billion and $0.67, respectively, compared to $3.7 billion and $0.61 in 3Q16. Pfizer reported YTD September 2017 adjusted income and adjusted diluted EPS of $12.3 billion and $2.03, respectively, compared to $11.9 billion and $1.92 in YTD September 2016.
Interested in IVV? Don't miss the next report.
Receive e-mail alerts for new research on IVV
In 3Q17, Pfizer reported the cost of sales of $2.8 billion compared to $3.1 billion in 3Q16. In 3Q17, Pfizer reported SI&A (selling, informational, and administrative) and R&D (research and development) expenses of $3.5 billion and $1.9 billion, respectively, compared to $3.6 billion and $1.9 billion in 3Q16.
Pfizer reported YTD September 2017 cost of sales, SI&A, and R&D expenses of $8.0 billion, $10.2 billion, and $5.3 billion, respectively, compared to around $9.1 billion, $10.4 billion, and $5.4 billion in YTD September 2016.
Peers Johnson & Johnson (JNJ), Merck (MRK), and Novartis (NVS) reported revenues of $19.7 billion, $10.3 billion, and $12.4 billion, respectively. The revenue growth of Pfizer could boost the iShares Core S&P 500 ETF (IVV). Johnson & Johnson and Pfizer make up about ~1.7% and ~0.95% of IVV’s total portfolio holding, respectively.